Mobile

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-de...

Update Il y a 4 ans
Reference: EUCTR2006-003971-11

A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-dependent iron overload

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to evaluate if fixed starting doses of ICL670, dependent on transfusion history, and subsequent dose titration can provide clinically acceptable chelation among low and INT-1 risk MDS patients.

Inclusion criteria

  • myelodysplastic syndrome and transfusion-dependent iron overload

Links